HBM Holdings-B (02142) Receives NMPA IND Approval for Long-Acting Bispecific Antibody HBM7575 Targeting Atopic Dermatitis

Bulletin Express03-09

On 9 March 2026, HBM Holdings-B (02142) announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HBM7575 (also known as SKB575), authorising clinical trials in patients with atopic dermatitis.

HBM7575/SKB575 is a long-acting bispecific antibody that blocks thymic stromal lymphopoietin (TSLP) and a second antigen, aiming to inhibit TSLP-mediated Th2 immune activation while generating a synergistic effect through dual target engagement. The molecule is engineered for an extended half-life designed to enable subcutaneous dosing intervals exceeding three months, positioning it as a potential best-in-class therapy.

Development responsibilities, including global clinical programmes and commercialisation, are led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK). Under the collaboration agreement, HBM Holdings-B contributes to investment and development and will share in future returns from the asset.

The company cautions that successful development and marketing of HBM7575/SKB575 are not guaranteed and advises shareholders and potential investors to exercise due care when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121103180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121103180","market":"us","top_or_hot":-1,"title":"HBM Holdings-B (02142) Receives NMPA IND Approval for Long-Acting Bispecific Antibody HBM7575 Targeting Atopic Dermatitis","media":"Bulletin Express","content":"<p>On 9 March 2026, HBM Holdings-B (02142) announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HBM7575 (also known as SKB575), authorising clinical trials in patients with atopic dermatitis.</p>\n<p>HBM7575/SKB575 is a long-acting bispecific antibody that blocks thymic stromal lymphopoietin (TSLP) and a second antigen, aiming to inhibit TSLP-mediated Th2 immune activation while generating a synergistic effect through dual target engagement. The molecule is engineered for an extended half-life designed to enable subcutaneous dosing intervals exceeding three months, positioning it as a potential best-in-class therapy.</p>\n<p>Development responsibilities, including global clinical programmes and commercialisation, are led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK). Under the collaboration agreement, HBM Holdings-B contributes to investment and development and will share in future returns from the asset.</p>\n<p>The company cautions that successful development and marketing of HBM7575/SKB575 are not guaranteed and advises shareholders and potential investors to exercise due care when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings-B (02142) Receives NMPA IND Approval for Long-Acting Bispecific Antibody HBM7575 Targeting Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings-B (02142) Receives NMPA IND Approval for Long-Acting Bispecific Antibody HBM7575 Targeting Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-09 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 9 March 2026, HBM Holdings-B (02142) announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HBM7575 (also known as SKB575), authorising clinical trials in patients with atopic dermatitis.</p>\n<p>HBM7575/SKB575 is a long-acting bispecific antibody that blocks thymic stromal lymphopoietin (TSLP) and a second antigen, aiming to inhibit TSLP-mediated Th2 immune activation while generating a synergistic effect through dual target engagement. The molecule is engineered for an extended half-life designed to enable subcutaneous dosing intervals exceeding three months, positioning it as a potential best-in-class therapy.</p>\n<p>Development responsibilities, including global clinical programmes and commercialisation, are led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK). Under the collaboration agreement, HBM Holdings-B contributes to investment and development and will share in future returns from the asset.</p>\n<p>The company cautions that successful development and marketing of HBM7575/SKB575 are not guaranteed and advises shareholders and potential investors to exercise due care when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1121103180","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121103180","pubTimestamp":1773045799,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 9 March 2026, HBM Holdings-B (02142) announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HBM7575 (also known as...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"HBM Holdings-B(02142)靶向特应性皮炎的长效双特异性抗体HBM7575获NMPA IND批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"On 9 March 2026, HBM Holdings-B (02142) announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HBM7575 (also known as SKB575), authorising clinical trials in patients with atopic dermatitis.\nHBM7575/SKB575 is a long-acting bispecific antibody that blocks thymic stromal lymphopoietin (TSLP) and a second antigen, aiming to inhibit TSLP-mediated Th2 immune activation while generating a synergistic effect through dual target engagement. The molecule is engineered for an extended half-life designed to enable subcutaneous dosing intervals exceeding three months, positioning it as a potential best-in-class therapy.\nDevelopment responsibilities, including global clinical programmes and commercialisation, are led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK). Under the collaboration agreement, HBM Holdings-B contributes to investment and development and will share in future returns from the asset.\nThe company cautions that successful development and marketing of HBM7575/SKB575 are not guaranteed and advises shareholders and potential investors to exercise due care when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121103180","isCrawlerRequest":true}